HemoSonics-UVA Cardiac Surgery Clinical Study Protocol
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Clot time
研究概览
简要总结
This study compares the results of current standard coagulation measurement devices to the Quantra System, a new device, using small amount of extra blood obtained during routine blood draws in cardiac surgery patients.
详细描述
HemoSonics is developing a novel POC diagnostic device, the Quantra System, to perform whole blood coagulation analysis and which is suitable for use in surgical and intensive care settings. The Quantra System employs a patented technology named sonorheometry, which was invented at the University of Virginia. Sonorheometry uses ultrasound pulses to characterize the dynamic changes in viscoelastic properties of a blood sample during coagulation and clot lysis. The initial assay performed on the Quantra System will be the surgical assay for monitoring hemostasis during major surgical procedures in adult patients.
A clinical study will be conducted to evaluate the analytical performance as well as provide a preliminary evaluation of the performance comparability of the HemoSonics' device as compared to existing coagulation monitoring technology in heart surgery. This study will be performed at HemoSonics and the University of Virginia Health System and will involve patients undergoing cardiac surgery requiring bypass.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is scheduled for cardiac surgery involving bypass circuit
- •Subject is older than 18 years
- •Subject is willing to participate and he/she has signed a consent form
排除标准
- •Subject is unable to provide written informed consent
- •Subject is incarcerated at the time of the study
- •Subject is affected by any condition that, in the opinion of the surgical team, may pose additional risks
- •Patients with renal disease (defined as serum creatinine greater than 1.5 mg/dl)
- •Patients with history of active liver disease
- •Patients on emergency cases
- •Patients on heparin anticoagulation before the beginning of the study
结局指标
主要结局
Clot time
时间窗: 1 day
Coagulation Function
Clot Amplitude
时间窗: 1 day
Coagulation Function
次要结局
未报告次要终点
研究者
Danja Groves, MD
Associate Professor, Anesthesiology
University of Virginia